Myriad Genetics (MYGN)
Offers hereditary cancer, tumor profiling, prenatal, and GeneSight pharmacogenomic tests.
Something off on this page? Send us feedback.
Sells molecular diagnostic and precision medicine tests across oncology, women's health, and mental health. Revenue is disclosed by hereditary cancer, tumor profiling, prenatal, and mental health categories while operations are managed as one segment.
Runs a molecular diagnostics and precision medicine test menu anchored in oncology, women's health, and mental health. Current brands include MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, Precise Tumor, Precise MRD, Prequel, Foresight, FirstGene, SneakPeek, and GeneSight.
Extends the original BRCA cancer-risk franchise into tumor profiling, prenatal testing, and pharmacogenomics. Assurex added GeneSight in mental health, while Counsyl added reproductive genetic testing capabilities that support the women's-health portfolio.
Operates from Salt Lake City under one reporting segment. Execution depends on reimbursement coverage, companion-diagnostic approvals, product launches such as Precise MRD, and the broader post-BRCA patent environment.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Reiterate | Rating: —Target: $6 | Target: $3.60 |
| Sep 1, 2026 | Piper Sandler | Downgrade | Target: $12.50 | Target: $2 |
| Aug 18, 2026 | Stephens | Target | Target: $22 | Target: $3 |
| Aug 3, 2026 | Wells Fargo | Reiterate | Rating: —Target: $6 | Target: $3 |
| Feb 24, 2026 | UBS | Reiterate | Rating: —Target: $8 | Target: $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $115.2M · Total debt $210.5M · Total assets $638.9M · Shareholders' equity $303.9M
- Revenue
- $190.7M
- Operating income
- −$38.9M
- Net income
- −$43.2M
No dividends on record.
| Institutions | 94.84% | 90.71M shares | |
|---|---|---|---|
| 200 holders · as of Jun 30, 2026 | |||
| Insiders | 6.28% | 6.00M shares | |
| 21 holders · as of Sep 22, 2026 | |||
| Strategic holders | 20.94% | 20.03M shares | |
| 3 holders · as of Sep 4, 2026 | |||
| Adds to | 122.06% | ||
95.65M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 122.06%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 11.39% | 10.89M | as of Jun 30, 2026 |
BlackRock Portfolio Management LLCStrategic | 10.35% | 9.90M | filed Sep 4, 2026 |
Millennium Management LLCInstitution | 6.92% | 6.62M | as of Jun 30, 2026 |
Vestal Point Capital, LPInstitution | 6.00% | 5.74M | as of Jun 30, 2026 |
Integrated Core Strategies (US) LLCStrategic | 5.42% | 5.18M | filed Feb 11, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 8, 2026 | Rashmi Kumar | director | −15,000 | $4.46 |
| May 14, 2026 | Paul Bisaro | director | +7,500 | $3.69 |
| Mar 9, 2026 | Samraat S. Raha | director, officer: President and CEO | +40,000 | $5.00 |
| Feb 25, 2026 | S. Louise Phanstiel | director | +6,100 | $4.74 |
| Feb 26, 2026 | S. Louise Phanstiel | director | +50,407 | $4.80 |
- Natera
Broad overlap in prenatal, hereditary cancer, and MRD testing
- Tempus AI
Direct overlap in oncology, hereditary cancer, and GeneSight PGx
- Labcorp
Scale lab rival across genetics, oncology, prenatal, and PGx
- BillionToOne
Direct prenatal challenger with growing oncology liquid biopsy
- Quest Diagnostics
National lab rival in advanced diagnostics and genetic testing
- Guardant Health
Precision-oncology rival in tumor profiling, CDx, and MRD
- Caris Life Sciences
Precision-oncology rival in molecular profiling and therapy selection
- Veracyte
Cancer classifier rival centered on prostate genomics
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Myriad Genetics | $4.02 | −0.00% | $379.7M | — | — | 0.5 | −10.5% |
| Natera | $389.88 | −0.26% | $55.98B | — | — | 20.7 | +37.7% |
| Tempus AI | $76.92 | −0.35% | $13.52B | — | — | 9.4 | +21.6% |
| Labcorp | $311.75 | +0.07% | $25.55B | 25.8 | 16.5 | 1.8 | +5.8% |
| BillionToOne | $115.47 | −0.52% | $5.34B | 187.2 | 147.2 | 13.4 | +64.3% |
| Quest Diagnostics | $237.42 | +1.13% | $25.92B | 24.9 | 20.7 | 2.2 | +10.2% |
| Guardant Health | $176.88 | −0.16% | $23.77B | — | — | 20.1 | +44.3% |
| Caris Life Sciences | $31.38 | −0.28% | $8.90B | 87.9 | 124.6 | 9.0 | +45.4% |
| Veracyte | $42.65 | −1.64% | $3.46B | 31.0 | 23.5 | 6.2 | +15.5% |
| Median | 31.0 | 23.5 | 9.2 | +29.6% |